Polarean Imaging (GB:POLX) has released an update.
Polarean Imaging plc has announced the submission of a supplemental New Drug Application to the FDA seeking approval to lower the minimum age for use of their lung imaging contrast agent XENOVIEW™ to children aged six and older. XENOVIEW™ is currently approved for lung ventilation MRI in adults and children aged 12 and up. The company aims to enhance disease management in younger pediatric patients with this expansion.
For further insights into GB:POLX stock, check out TipRanks’ Stock Analysis page.
